세계의 흡입식 조직 유방 생검 기기(VABB) 시장 규모는 2023년 8억 1,185만 달러로 평가되었고, 2024년 9억 684만 달러에서 2032년에는 21억 9,763만 달러로 성장할 전망이며, 예측 기간 2025년부터 2032년까지의 CAGR은 11.7%로 성장할 전망입니다.
흡입식 조직 유방 생검 기기(VABB) 시장은 세계적으로 여성이 앓는 가장 흔한 질환 중 하나인 유방암의 유병률 증가를 주요인으로 하여 큰 성장을 이루고 있습니다. VABB 기기는 신속한 대응 시간, 뛰어난 조직 채취 능력, 높은 진단 정확도로 기존 생검법보다 지지를 받고 있으며, 그 결과 암의 놓치는 비율이 감소하고 조직학적 과소평가가 감소합니다. 유방암이 여성의 암 관련 사인의 제2위를 차지하는 가운데, 세계 각국의 정부에 의한 조기 발견에 대한 의식의 고조가 VABB 기기의 수요를 뒷받침하고 있습니다. 이 동향은 혁신적인 진단 기술을 통해 여성의 건강 상태를 개선하려는 광범위한 노력을 반영하고 있습니다. VABB 기기 시장은 향후 몇 년간 지속적으로 확대될 전망입니다.
Global Vacuum-Assisted Breast Biopsy Device Market size was valued at USD 811.85 million in 2023 and is poised to grow from USD 906.84 million in 2024 to USD 2197.63 million by 2032, growing at a CAGR of 11.7% during the forecast period (2025-2032).
The vacuum-assisted breast biopsy (VABB) market is witnessing significant growth, primarily driven by the increasing prevalence of breast cancer, one of the most common diseases affecting women globally. VABB devices are favored over traditional biopsy methods due to their rapid response times, superior tissue collection capabilities, and higher diagnostic accuracy, which results in a lower cancer miss rate and reduced histological underestimates. As breast cancer ranks as the second-leading cause of cancer-related deaths among women, heightened awareness initiatives for early detection by governments worldwide are propelling the demand for VABB devices. This trend reflects a broader commitment to improving women's health outcomes through innovative diagnostic technologies. The market for VABB devices is poised for continued expansion in the coming years.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Vacuum-Assisted Breast Biopsy Device market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Vacuum-Assisted Breast Biopsy Device Market Segmental Analysis
Global Vacuum-Assisted Breast Biopsy Device Market is segmented by Product, Type, Technique, Applications, End User and region. Based on Product, the market is segmented into Core Needle Biopsy Devices, Vacuum-assisted Biopsy Devices, Fine Needle Aspiration Biopsy Devices, Surgical Biopsy Devices and Others. Based on Type, the market is segmented into 9-12G, <9G and >12G. Based on Technique, the market is segmented into Ultrasound-Guided Biopsy, Stereotactic-Guided Biopsy, MRI-Guided Biopsy and Others. Based on Applications, the market is segmented into Breast Biopsy, Lung Biopsy, Colorectal Biopsy, Prostate Biopsy and Others. Based on End User, the market is segmented into Hospitals, Academic And Research Institutes, Diagnostic And Imaging Centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Vacuum-Assisted Breast Biopsy Device Market
The Vacuum-Assisted Breast Biopsy (VABB) device market is poised for significant growth, primarily driven by the high accuracy and efficiency that these devices offer compared to traditional biopsy procedures. VABB devices are preferred because they can collect a larger volume of tissue samples in contiguous sections, allowing for multiple specimens to be obtained with a single needle insertion. This results in more precise diagnoses, a reduced rate of missed cancers, and fewer histological underestimations. Furthermore, VABB is effective for the therapeutic removal of benign lesions like fibroadenomas, which decreases reliance on open surgical biopsies, leading to lower healthcare costs associated with hospital stays and surgical interventions. Consequently, these advantages are propelling market expansion for VABB devices.
Restraints in the Global Vacuum-Assisted Breast Biopsy Device Market
A significant restraint in the Global Vacuum-Assisted Breast Biopsy Device (VABB) market is the high cost associated with these devices. The capital expenditure for VABB includes not only the vacuum generators and biopsy handpieces but also increased operational expenses related to consumables like needles, tubing, and localizing markers. This elevated cost, when compared to alternative methods such as Fine Needle Aspiration (FNA) or core biopsies, often restricts VABB to a secondary role in many medical facilities. It is typically employed only after initial procedures have either yielded inconclusive results or presented conflicting findings between imaging and pathology, limiting its widespread adoption.
Market Trends of the Global Vacuum-Assisted Breast Biopsy Device Market
The global vacuum-assisted breast biopsy device market is experiencing robust growth, driven by advancing research initiatives focused on enhancing early breast cancer detection through accurate and minimally invasive procedures. Innovations in technology have led to the emergence of advanced devices that provide greater precision and patient comfort, fueling demand. Additionally, supportive government policies and funding aimed at strengthening cancer research frameworks contribute to a conducive environment for the development of these diagnostic tools. This heightened awareness and emphasis on early diagnosis are expected to propel market expansion, as healthcare systems increasingly prioritize effective cancer management strategies.